Clinical Trial for Mesothelioma Patients: Bortezomib and Cisplatin Study Criteria
Read about the study criteria for a current clinical trial being conducted to study the effects of Bortezomib and Cisplatin for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. This study is being conducted ONLY in the United Kingdom.
Study Phase, Type and Design: Interventional; Treatment, Non Randomized, Open Label
Primary Outcome Measures:
• Progression-free survival (PFS) rate at 18 weeks
Secondary Outcome Measures:
• Overall objective response rate• Symptomatic response rate
• Safety as measured by NCI CTCAE v3.0 and the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire
• Duration of PFS
• Overall survival
Recruitment Information:
Recruitment status: Recruiting
Enrollment: 76
Start Date: February 2007
Ending Date: December 2009 (Final data collection date for primary outcome measure)
Detailed Description:
OBJECTIVES:
• Determine the activity and safety of Bortezomib and Cisplatin as first-line treatment in patients with malignant mesothelioma.
• Validate the use of progression-free survival rate as a primary endpoint for the design of phase II mesothelioma trials.
Disease Characteristics:
• Histologically confirmed pleural malignant mesothelioma, meeting 1 of the following criteria:o Recurrent disease after radical surgery
o Disease not considered suitable for radical treatment
• Measurable or evaluable disease
• No clinical evidence of brain or leptomeningeal metastases
Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health
Other helpful links:
Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney

Description of program to treat mesothelioma patients with Bortezomib